Edition:
United Kingdom

Athenex Inc (ATNX.OQ)

ATNX.OQ on NASDAQ Stock Exchange Global Select Market

15.96USD
8 Dec 2017
Change (% chg)

$0.25 (+1.59%)
Prev Close
$15.71
Open
$15.88
Day's High
$16.26
Day's Low
$15.86
Volume
59,480
Avg. Vol
56,658
52-wk High
$20.43
52-wk Low
$11.25

Select another date:

Fri, Dec 1 2017

BRIEF-Athenex Announces Planned Retirement Of Chief Financial Officer Nick Riehle

* ATHENEX ANNOUNCES PLANNED RETIREMENT OF CHIEF FINANCIAL OFFICER NICK RIEHLE

BRIEF-Athenex announces Q3 revenue of $14 million

* Says ‍company raises full-year revenue guidance to range of $33 million - $35 million​

BRIEF-Athenex announces positive recommendations from the ‍DSMB to continue the oraxol phase iii program

* Athenex announces positive recommendations from the Drug Safety Monitoring Board to continue the oraxol phase iii program

BRIEF-Athenex Inc announces first patient recruitment in phase III clinical trials for KX-01 ointment

* Athenex, Inc. announces first patient recruitment in phase III clinical trials for KX-01 ointment for actinic keratosis

BRIEF-Athenex Inc announces second quarter 2017 results

* Athenex Inc - ‍expect full-year revenues in range of $30 million to $34 million, inclusive of opportunity created by U.S. sodium bicarbonate shortage​ Source text for Eikon: Further company coverage:

BRIEF-Athenex announces approval of tax incentives from State of New York for Dunkirk facility

* Athenex inc - ‍obtained new york state and local tax incentives related to its pharmaceutical manufacturing facility in town of dunkirk, new york​

BRIEF-Athenex reports commencement of patient enrollment for oraxol-plus-ramucirumab phase 1b clinical trial in gastric cancer

* Athenex Inc. announces commencement of patient enrollment for oraxol-plus-ramucirumab phase 1b clinical trial in gastric cancer Source text for Eikon: Further company coverage:

BRIEF-Huateng Ma reports 11.6 pct passive stake in Athenex

* Huateng Ma reports 11.6 percent passive stake in Athenex Inc as of June 14 - SEC filing Source: (http://bit.ly/2ueJu6F) Further company coverage:

BRIEF-Athenex submits IND application of oraxol to Chinese FDA

* Athenex Inc announces submission of investigational new drug application of oraxol to Chinese FDA

BRIEF-Chongqing Lummy Pharma's unit subscribe to s US company Athenex's convertible bonds

* Says U.S. bio pharma company Athenex finished initial public offering

Select another date: